期刊文献+

晚期肿瘤维持治疗疗效评判的研究进展 被引量:2

Research Progress on Efficacy Evaluation in Maintenance Treatment for Advanced Cancer Patients
原文传递
导出
摘要 晚期肿瘤维持治疗即一线治疗得到临床获益病情稳定后,继续采用药物治疗达到改善生活质量、延缓肿瘤进展、提高存活率的目的。维持治疗的停药指征为疾病进展或出现不可耐受的不良反应。及时调整二线治疗方案以延长患者生存期的方式已经得到认可。因此,临床上迫切需要一种判断维持治疗疗效、确定更换二线治疗时机的预测指征。全文就影像学、肿瘤标志物、临床表现和分子检测等常见的疗效评价手段作一综述。 When the clinical benefit and stable condition are achieved for patients with advanced cancer,the purpose of maintenance treatment is to improve the quantity of life,to delay tumor progression,and to prolong the survival of patients. The terminal point of maintenance treatment is the progression of disease or intolerable adverse effects. It has been generally recognized that to early discover the progression and to adjust second-line therapeutic protocol can prolong the survival. So it is necessary to have indicators for evaluating the efficacy of maintenance treatment and the time of scheduling second-line chemotherapy. In this review,the commonly used evaluation means are discussed,including imaging,tumor markers,molecular detection and clinical features.
作者 连洁 杨宇 LIAN Jie;YANG Yu(Second Affiliated Hospital of Harbin Medical University,Harbin 150081,China)
出处 《肿瘤学杂志》 CAS 2019年第1期59-62,共4页 Journal of Chinese Oncology
关键词 维持治疗 肿瘤进展 循环肿瘤细胞 maintenance treatment tumor progression circulation tumor cell
  • 相关文献

参考文献2

二级参考文献37

  • 1Mizuki Nishino,Anita Giobbie-Hurder,Maria Gargano,Margaret Suda,Nikhil H. Ramaiya,F. Stephen Hodi.Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements[J]. Clinical Cancer Research . 2013 (14)
  • 2Thomas J. Lynch,Igor Bondarenko,Alexander Luft,Piotr Serwatowski,Fabrice Barlesi,Raju Chacko,Martin Sebastian,Joel Neal,Haolan Lu,Jean-Marie Cuillerot,Martin Reck.Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study[J]. Journal of Clinical Oncology . 2012 (17)
  • 3E.A. Eisenhauer,P. Therasse,J. Bogaerts,L.H. Schwartz,D. Sargent,R. Ford,J. Dancey,S. Arbuck,S. Gwyther,M. Mooney,L. Rubinstein,L. Shankar,L. Dodd,R. Kaplan,D. Lacombe,J. Verweij.New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)[J]. European Journal of Cancer . 2008 (2)
  • 4Riccardo Lencioni,Josep Llovet.Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma[J].Semin Liver Dis.2010(01)
  • 5JulienEdeline,EvelineBoucher,YanRolland,ElodieVauléon,MarcPracht,ChristophePerrin,CatherineLe Roux,Jean‐LucRaoul.Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma[J].Cancer.2011(1)
  • 6Christopher L. Wolfgang,Joseph M. Herman,Daniel A. Laheru,Alison P. Klein,Michael A. Erdek,Elliot K. Fishman,Ralph H. Hruban.Recent progress in pancreatic cancer[J].CA A Cancer Journal for Clinicians.2013(5)
  • 7Hidetoshi Eguchi,Hiroaki Nagano,Shogo Kobayashi,Koichi Kawamoto,Hiroshi Wada,Naoki Hama,Yoshito Tomimaru,Hirofumi Akita,Daisuke Sakai,Taroh Satoh,Toshihiro Kudo,Fumiaki Isohashi,Masaki Mori,Yuichiro Doki.A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer[J].Cancer Chemotherapy and Pharmacology.2014(2)
  • 8Tyvin Rich,Hoffman,Safran,Kathy Winter,Willett,Kimberly Perez,Mika Cline-Burkhardt,Robert Myerson,Rani Anne,Beth Erickson.Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer[J].OncoTargets and Therapy (default).2012(default)
  • 9Masato Ozaka,Yuji Matsumura,Hiroshi Ishii,Yasushi Omuro,Takao Itoi,Hisatsugu Mouri,Keiji Hanada,Yasutoshi Kimura,Iruru Maetani,Yoshinobu Okabe,Masaji Tani,Takaaki Ikeda,Susumu Hijioka,Ryouhei Watanabe,Shinya Ohoka,Yuki Hirose,Masafumi Suyama,Naoto Egawa,Atsushi Sofuni,Takaaki Ikari,Toshifusa Nakajima.Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)[J].Cancer Chemotherapy and Pharmacology.2012(5)
  • 10Susannah Yovino,Bert W. Maidment,Joseph M. Herman,Naimish Pandya,Olga Goloubeva,Chris Wolfgang,Richard Schulick,Daniel Laheru,Nader Hanna,Richard Alexander,William F. Regine.Analysis of Local Control in Patients Receiving IMRT for Resected Pancreatic Cancers[J].International Journal of Radiation Oncology Biology Physics.2012(3)

共引文献39

同被引文献44

引证文献2

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部